Market revenue in 2023 | USD 941.3 million |
Market revenue in 2030 | USD 1,615.1 million |
Growth rate | 8% (CAGR from 2023 to 2030) |
Largest segment | Synthetic |
Fastest growing segment | Biotech |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Synthetic, Biotech |
Key market players worldwide | Basf SE, CordenPharma, Bristol-Myers Squibb Co, Pfizer Inc, Boehringer Ingelheim Pharma, Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries, Albany Molecular Research, Sanofi SA, Lonza Group Ltd, Cipla Ltd DR, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, Novartis AG ADR, Roche Holding AG |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to high potency active pharmaceutical ingredients market will help companies and investors design strategic landscapes.
Synthetic was the largest segment with a revenue share of 73.62% in 2023. Horizon Databook has segmented the Japan high potency active pharmaceutical ingredients market based on synthetic, biotech covering the revenue growth of each sub-segment from 2018 to 2030.
Japan continues to be the one of the largest high potency active pharmaceutical ingredients markets in Asia Pacific. Rapidly aging population and increasing expectations for improved quality of life in Japan are propelling the market growth. According to World Economic Forum, in 2019, one-third of Japan's population is over the age of 65, and the country is considered to have the world’s oldest population.
The healthcare expenditure in Japan is also expected to increase sharply in proportion with GDP owing to the large elderly population. The healthcare system in Japan insists upon proper health maintenance. Moreover, MHLW has favorable policies for generic and biosimilar manufacturers, which allow the nation to supply active pharmaceutical ingredients at competitive prices.
Increasing number of patients suffering from lifestyle-induced diseases and chronic diseases is boosting the demand for drugs that help ease the pain, balance lost functions, and improve the overall quality of life. Thus, owing to the need for improved disease management, Japan high potency active pharmaceutical ingredients market is expected to exhibit steady growth over the forecast period.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan high potency active pharmaceutical ingredients market , including forecasts for subscribers. This country databook contains high-level insights into Japan high potency active pharmaceutical ingredients market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account